Metabolic and Vascular Effects of Tumor Necrosis Factor-α Blockade with Etanercept in Obese Patients with Type 2 Diabetes
- 20 October 2005
- journal article
- clinical trial
- Published by S. Karger AG in Journal of Vascular Research
- Vol. 42 (6), 517-525
- https://doi.org/10.1159/000088261
Abstract
The pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) impairs insulin action in insulin-sensitive tissues, such as fat, muscle and endothelium, and causes endothelial dysfunction. We hypothesized that TNF-alpha blockade with etanercept could reverse vascular and metabolic insulin resistance. Twenty obese patients with type 2 diabetes were randomized to etanercept treatment (25 mg subcutaneously twice weekly for 4 weeks) or used as controls in an open parallel study. Forearm blood flow and glucose uptake were measured during intra-arterial infusions of serotonin, sodium nitroprusside and insulin co-infused with serotonin. Beta-cell function was assessed with oral and intra-venous glucose tolerance tests and whole-body insulin sensitivity by hyperinsulinemic euglycemic clamps. Plasma levels of C-reactive protein and interleukin-6 decreased significantly with etanercept (C-reactive protein from 9.9 +/- 3.1 to 4.8 +/- 1.4 mg l(-1), p = 0.04; interleukin-6 from 3.1 +/- 0.4 to 1.9 +/- 0.2 ng l(-1), p = 0.03). Vasodilatory responses to serotonin and sodium nitroprusside infusions remained unchanged. Insulin effect on vasodilatation and on whole-body and forearm glucose uptake remained unchanged as well. Beta-cell function tended to improve. Although short-term etanercept treatment had a significant beneficial effect on systemic inflammatory markers, no improvement of vascular or metabolic insulin sensitivity was observed.Keywords
This publication has 43 references indexed in Scilit:
- ACE inhibitors and statins acutely improve endothelial dysfunction of human coronary arteriolesAmerican Journal of Physiology-Heart and Circulatory Physiology, 2004
- Salicylic Acid Reverses Phorbol 12-Myristate-13-Acetate (PMA)- and Tumor Necrosis Factor α (TNFα)-induced Insulin Receptor Substrate 1 (IRS1) Serine 307 Phosphorylation and Insulin Resistance in Human Embryonic Kidney 293 (HEK293) CellsJournal of Biological Chemistry, 2003
- Transmembrane Tumor Necrosis Factor (TNF)-α Inhibits Adipocyte Differentiation by Selectively Activating TNF Receptor 1Published by Elsevier ,1999
- EtanerceptDrugs, 1999
- Relation Between Plasma Tumor Necrosis Factor-α and Insulin Sensitivity in Elderly Men With Non–Insulin-Dependent Diabetes MellitusArteriosclerosis, Thrombosis, and Vascular Biology, 1998
- TNF‐α inhibits glucose‐induced insulin secretion in a pancreatic β‐cell line (INS‐1)FEBS Letters, 1995
- Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance.JCI Insight, 1995
- The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase.JCI Insight, 1995
- Comparison of near-infrared light spectroscopy, bioelectrical impedance and tritiated water techniques for the measurement of fat-free mass in humansScandinavian Journal of Clinical and Laboratory Investigation, 1992
- Coronary atherosclerotic plaques with and without thrombus in ischemic heart syndromes: A morphologic, immunohistochemical, and biochemical studyThe American Journal of Cardiology, 1991